Axsome Therapeutics Readies Auvelity Alzheimer's Agitation Launch, Expands CNS Pipeline

Axsome Therapeutics NASDAQ: AXSM executives said the company is preparing to launch Auvelity in Alzheimer's disease agitation this month while continuing to expand the drug's use in major depressive disorder and advance a broad central nervous system pipeline.